Kailera CMO receives new stock option awards

Kailera Therapeutics, Inc. granted Chief Medical Officer Scott M. Wasserman two stock option awards, each covering 100,000 shares of common stock at an exercise price of $16.00 per share and expiring on April 16, 2036.

Rhea-AI Filing Summary

Kailera Therapeutics, Inc. granted Chief Medical Officer Scott M. Wasserman two stock option awards, each covering 100,000 shares of common stock at an exercise price of $16.00 per share and expiring on April 16, 2036.

One option grant vests 25% on April 16, 2027 and then in 36 equal monthly installments, contingent on continued service. The other becomes exercisable only if the company’s stock price reaches at least $40 per share during a defined performance measurement period or in a qualifying change in control, also subject to continued service.

Insider Trade Summary

Grant/Award: 200,000 shares

Grant/Award 2 txns

Insider Wasserman Scott M.

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	100,000	$0.00	$0.00
Grant/Award	Stock Option (right to buy)	100,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 200,000 contracts (Direct)

Footnotes (2)

1. F1. The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
2. F2. The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.

Key Figures

Option grant size: 100,000 shares Exercise price: $16.00 per share Option expiration: April 16, 2036 +5 more

8 metrics

Option grant size 100,000 shares Underlying common stock per option award

Exercise price $16.00 per share Stock option exercise price for both grants

Option expiration April 16, 2036 Expiration date for the reported options

Initial time-based vesting 25% on April 16, 2027 First vesting tranche of one option grant

Subsequent time-based vesting 36 monthly installments Remaining vesting schedule after April 16, 2027

Performance vesting price hurdle $40.00 per share Stock price condition for performance-based vesting

Performance measurement period start October 16, 2026 Beginning of performance measurement period

Performance measurement period end April 16, 2030 End of performance measurement period

Key Terms

Stock Option (right to buy), Performance Measurement Period, change in control transaction, average daily closing price, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Performance Measurement Period financial

"the "Performance Measurement Period"), or (ii) the stock price"

change in control transaction financial

"or (ii) the stock price in a change in control transaction"

average daily closing price financial

"the average daily closing price of the Company's common stock"

continued service financial

"subject to the Reporting Person's continued service through such vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kailera Therapeutics (KLRA) disclose about its Chief Medical Officer in this Form 4?

Kailera Therapeutics reported that Chief Medical Officer Scott M. Wasserman received two stock option awards. Each option covers 100,000 shares of common stock at a $16.00 exercise price, providing equity-based compensation tied to both time-based and performance-based vesting conditions.

How many Kailera Therapeutics (KLRA) shares are covered by the new option grants?

Each of the two grants covers 100,000 underlying shares of common stock. The options were awarded at a grant price of $0.00 with a $16.00 per-share exercise price, giving the CMO potential future ownership if vesting and exercise conditions are satisfied.

What are the time-based vesting terms of the KLRA stock options granted to the CMO?

One option grant vests 25% of its underlying shares on April 16, 2027. The remaining shares vest in 36 substantially equal monthly installments thereafter, so long as Scott M. Wasserman continues providing service through each applicable vesting date.

What performance conditions apply to the performance-based Kailera (KLRA) option grant?

The performance-based options vest only if the company’s stock reaches at least $40 per share. This can occur via a 30-day average daily closing price on Nasdaq or a qualifying change in control price during the October 16, 2026 to April 16, 2030 performance period.

When do the newly granted Kailera Therapeutics (KLRA) options expire?

Both stock option awards reported for Scott M. Wasserman have an expiration date of April 16, 2036. If the options are not exercised by that date, they will lapse, subject to earlier termination under standard employment or equity plan provisions described by the company.

Are the Kailera (KLRA) option awards to the CMO open-market purchases or compensation grants?

The transactions are compensation-related grants, not open-market purchases or sales. They are coded as awards (transaction code A) with a grant price of $0.00 and represent equity incentives contingent on future vesting and exercise at the $16.00 per-share strike price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/20/2026 - 05:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wasserman Scott M.

(Last) (First) (Middle)

C/O KAILERA THERAPEUTICS, INC.

180 THIRD AVENUE, 4TH FLOOR

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kailera Therapeutics, Inc. [ KLRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16	04/16/2026		A		100,000		(1)	04/16/2036	Common Stock	100,000	$0	100,000	D
Stock Option (right to buy)	$16	04/16/2026		A		100,000		(2)	04/16/2036	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.

2. The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.

	/s/ John Mei, Attorney-in-fact	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)